Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 10/21 10:00:00 pm
98.91 USD   -1.11%
10/20 CELGENE : Oral OTEZLA® ▼ (Apremilast) Receives Positive Nice R..
10/19 CELGENE : Chesley Taft Associates buys $17,871,151 stake in Celgene ..
10/18 CELGENE CORPORA : CELG) Files An 8-K
News SummaryMost relevantAll newsSector news 

Celgene Corporation : to Webcast at Upcoming Investor Conferences and Analyst Day

share with twitter share with LinkedIn share with facebook
share via e-mail
04/29/2013 | 02:40pm CEST

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com. Celgene management will provide an overview of the Company.

Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock Conference at 1:20 p.m. ET.

Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.

Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global Healthcare Conference at 11:30 a.m. ET.

Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's 29th Annual Strategic Decisions Conference at 9:00 a.m. ET.

Additionally, Celgene plans to host an Analyst and Institutional Investor Day on May 6. The presentation will be webcast beginning at 1 p.m. ET and is expected to conclude at 5 p.m.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
10/20 CELGENE : to Present New Data on Investigational Compounds at UEGW and ACG Congr..
10/20 CELGENE : Patent Issued for Romidepsin Formulations and Uses (USPTO 9463215)
10/20 CELGENE : Inaugural Chief Medical Officer Joins Pancreatic Cancer Action Network..
10/20 CELGENE : Oral OTEZLA® ▼ (Apremilast) Receives Positive Nice Recommendatio..
10/19 CELGENE : Chesley Taft Associates buys $17,871,151 stake in Celgene Corporation
10/18 CELGENE CORPORATION : and Sage Bionetworks Announce Technology Collaboration to ..
10/18 CELGENE : Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Exte..
10/17 CELGENE CORP /DE/ : Other Events (form 8-K)
10/17 CELGENE : Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Exte..
More news
Sector news : Bio Therapeutic Drugs
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17DJPfizer Plans to Launch Remicade Biosimilar in November
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
10/22 S&P 500 WEEKLY UPDATE : A Stock Market In No Man's Land Searching For A Near Ter..
10/20 Collaborative Leukemia Trial Orbits Moonshot Initiative
10/20 England's NHS advisor backs Celgene's Otezla
10/19 Celgene Dribbles Out Endoscopy Data At Last
10/19 This Core Biotech Idea Just Gave Us Another Reason To Buy
Financials ($)
Sales 2016 11 075 M
EBIT 2016 5 780 M
Net income 2016 3 503 M
Debt 2016 6 835 M
Yield 2016 -
P/E ratio 2016 24,13
P/E ratio 2017 17,35
EV / Sales 2016 7,54x
EV / Sales 2017 6,16x
Capitalization 76 667 M
More Financials
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 138 $
Spread / Average Target 40%
Consensus details
EPS Revisions
More Estimates Revisions
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.-2.35%118 623
GILEAD SCIENCES, INC.-26.58%98 037
ACTELION LTD17.34%16 178
More Results